BiotechTube

Octreotide LAR Depot

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastrointestinal Bleeding

Conditions

Gastrointestinal Bleeding

Trial Timeline

Feb 1, 2013 → Oct 1, 2014

NCT ID
NCT01707225

About Octreotide LAR Depot

Octreotide LAR Depot is a phase 1 stage product being developed by Novartis for Gastrointestinal Bleeding. The current trial status is completed. This product is registered under clinical trial identifier NCT01707225. Target conditions include Gastrointestinal Bleeding.

What happened to similar drugs?

8 of 20 similar drugs in Gastrointestinal Bleeding were approved

Approved (8) Terminated (3) Active (9)
✅Remimazolam TosilateJiangsu Hengrui MedicineApproved
✅Mycophenolate SodiumNovartisApproved
✅myforticNovartisApproved
✅Imatinib MesylateNovartisApproved
✅Imatinib mesylateNovartisApproved
✅NilotinibNovartisApproved
✅Sunitinib Malate (SU011248)PfizerApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01707225Phase 1Completed

Competing Products

20 competing products in Gastrointestinal Bleeding

See all competitors
ProductCompanyStageHype Score
Raludotatug Deruxtecan (R-DXd)Daiichi SankyoPhase 2
39
Patritumab deruxtecanDaiichi SankyoPhase 1/2
39
DS-6157aDaiichi SankyoPhase 1
21
DS-8201a + Physician's ChoiceDaiichi SankyoPhase 2
35
Naldemedine + PlaceboShionogiPhase 2
27
GemcitabineEli LillyPhase 1/2
32
OlaratumabEli LillyPhase 2
27
pemetrexed + cisplatinEli LillyPhase 2
35
cetuximabEli LillyPhase 2
35
BBI503Sumitomo PharmaPhase 2
27
BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + RegorafenibSumitomo PharmaPhase 1/2
32
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
40
Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol)Johnson & JohnsonPhase 2
35
Remimazolam TosilateJiangsu Hengrui MedicineApproved
43
Famitinib capsules + Sunitinib CapsulesJiangsu Hengrui MedicinePhase 3
32
FamitinibJiangsu Hengrui MedicinePhase 2
31
Esomeprazole IV + Omeprazole IVAstraZenecaPhase 3
40
Durvalumab + FLOT chemotherapyAstraZenecaPhase 3
44
EsomeprazoleAstraZenecaPhase 3
40
AZD2171AstraZenecaPhase 2
35